Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.

Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.

Multiple myeloma is characterized by the growth of plasma cells in the bone marrow and the development of osteolytic bone disease. Myeloma cells are found closely associated with bone, and targeting this environment may therefore affect both the bone disease and the growth of myeloma cells. We have...

Deskribapen osoa

Xehetasun bibliografikoak
Egile Nagusiak:	Croucher, P, De Hendrik, R, Perry, M, Hijzen, A, Shipman, C, Lippitt, J, Green, J, Van Marck, E, Van Camp, B, Vanderkerken, K
Formatua:	Journal article
Hizkuntza:	English
Argitaratua:	2003

Antzeko izenburuak

Zoledronic acid prevents the development of myeloma bone disease and increases survival
nork: Shipman, C, et al.
Argitaratua: (2002)

Zoledronic acid prevents the development of osteolytic bone disease and increases survival in a murine model of multiple myeloma
nork: Croucher, P, et al.
Argitaratua: (2002)

Zoledronic acid inhibits the development of osteolytic bone disease and increases disease free survival in a murine model of multiple myeloma.
nork: Croucher, P, et al.
Argitaratua: (2001)

Osteoprotegerin (OPG) inhibits the development of osteolytic bone disease in the 5T2MM model of multiple myeloma.
nork: Croucher, P, et al.
Argitaratua: (2000)

Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
nork: Croucher, P, et al.
Argitaratua: (2003)

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma.
nork: Croucher, P, et al.
Argitaratua: (2001)

The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma.
nork: Shipman, C, et al.
Argitaratua: (2000)

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma
nork: Croucher, P, et al.
Argitaratua: (2001)

Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma.
nork: Vanderkerken, K, et al.
Argitaratua: (2003)

Osteoprotegerin and the development of myeloma bone disease
nork: Croucher, P, et al.
Argitaratua: (2004)

Bisphosphonates and in vivo models of multiple myeloma - Reply
nork: Shipman, C, et al.
Argitaratua: (2001)

Myeloma cells can down-regulate release of osteoprotegerin (OPG) from human bone cells - A contributing factor in myeloma bone loss?
nork: Shipman, C, et al.
Argitaratua: (2002)

APOMINE (TM), a novel inhibitor of the meyalonate/isoprenoid pathway, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of the myeloma disease in vivo.
nork: Croucher, P, et al.
Argitaratua: (2002)

Bisphosphonates--mechanisms of action in multiple myeloma.
nork: Shipman, C, et al.
Argitaratua: (2000)

Myeloma cells isolated from patients with multiple myeloma express osteoprotegerin ligand.
nork: Shipman, C, et al.
Argitaratua: (2000)

Myeloma cells can promote osteoclastic activity rather than osteoclast recruitment in vitro; Evidence from the 5T2MM murine model of myeloma
nork: Mueller, G, et al.
Argitaratua: (2004)

Bone marrow endothelial cells express the osteoclastogenic factor RANKL and its decoy receptor OPG: Evidence for a role in the development of myeloma bone disease.
nork: De Leenheer, E, et al.
Argitaratua: (2002)

5T2MM murine myeloma cells and CD138+ve human myeloma cells promote osteoclastic activity rather than osteoclast formation in vitro
nork: Mueller, G, et al.
Argitaratua: (2004)

Bone marrow endothelial cells produce osteoprotegerin: Evidence for a role in the development of myeloma bone disease
nork: De Leenheer, E, et al.
Argitaratua: (2004)

Tumour cells isolated from patients with multiple myeloma express the critical osteoclastogenic factor, RANKL.
nork: Shipman, C, et al.
Argitaratua: (2000)

Intra-tumor delivery of zoledronate mitigates metastasis-induced osteolysis superior to systemic administration
nork: Anas Nooh, et al.
Argitaratua: (2017-03-01)

Retrospective Evaluation of Acute Kidney Injury After Zoledronic Acid Administration to Dogs With Malignant Osteolysis
nork: Sarah A. Vidal, et al.
Argitaratua: (2021-07-01)

The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel.
nork: Jagdev, S, et al.
Argitaratua: (2001)

Apomine, an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivo.
nork: Edwards, C, et al.
Argitaratua: (2007)

Thymosin β4 has tumor suppressive effects and its decreased expression results in poor prognosis and decreased survival in multiple myeloma
nork: Jo Caers, et al.
Argitaratua: (2010-01-01)

Soluble rank ligand produced by myeloma cells causes generalised bone loss in multiple myeloma.
nork: Clive Henry Buckle, et al.
Argitaratua: (2012-01-01)

Osteoprotegerin (OPG) is a soluble decoy receptor for TRAIL/Apo2L and can inhibit TRAIL/Apo2L-induced apoptosis of human myeloma cells in vitro.
nork: Shipman, C, et al.
Argitaratua: (2002)

Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.
nork: Shipman, C, et al.
Argitaratua: (2003)

Histone deacetylase inhibitors in multiple myeloma
nork: Sarah Deleu, et al.
Argitaratua: (2009-06-01)

Host Bone Marrow-Derived Stromal Cells Promote Myeloma Initiation and Development of Osteolysis
nork: Fowler, J, et al.
Argitaratua: (2008)

Reelin depletion alleviates multiple myeloma bone disease by promoting osteogenesis and inhibiting osteolysis
nork: Aixia Dou, et al.
Argitaratua: (2021-08-01)

Zoledronate suppressed angiogenesis and osteogenesis by inhibiting osteoclasts formation and secretion of PDGF-BB.
nork: Si-Yong Gao, et al.
Argitaratua: (2017-01-01)

Localized Osteolysis
nork: Mundy, G, et al.
Argitaratua: (2008)

Acro-osteolysis
nork: Joe Thomas, et al.
Argitaratua: (2019-04-01)

Anti-tumour activity of bisphosphonates in human myeloma cells.
nork: Shipman, C, et al.
Argitaratua: (1998)

Cells of the bone marrow microenvironment protect myeloma cells from apoptosis induced by TRAIL but not by agonists of TRAIL death receptors.
nork: Locklin, R, et al.
Argitaratua: (2005)

Zoledronic Acid Inhibits the Capacity of Myeloid-Immune Suppressor Cells in Myeloma to Form Osteoclasts.
nork: Zhuang, J, et al.
Argitaratua: (2008)

Pyroptosis in Periprosthetic Osteolysis
nork: Jian Yin, et al.
Argitaratua: (2022-11-01)

Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity.
nork: Shipman, C, et al.
Argitaratua: (1997)

Mesenchymal stem cells expressing osteoprotegerin variants inhibit osteolysis in a murine model of multiple myeloma
nork: Jerome T. Higgs, et al.
Argitaratua: (2017-11-01)